

1. Background

Approximately one-third of community-dwelling older adults complain of memory or other cognitive difficulties in their daily lives [1]. For some individuals, the selfperception of subjective cognitive decline (SCD) may represent a very early symptom of Alzheimer-type dementia that occurs before the onset of objective cognitive impairment [2]. Indeed, longitudinal reports have suggested that individuals with SCD are at risk for progression to both dementia and its precursor syndrome, mild cognitive impairment (MCI) [3,4]. In addition, studies using both in vivo biomarker tests [5,6] and postmortem brain autopsies [7-10] have identified pathologic evidence of Alzheimer's disease (AD) in those with SCD. Despite these findings, the hypothesis that SCD constitutes a preclinical stage of AD is not consistently supported by the research literature [11,12].

Characterizing the clinical markers of SCD is an important step toward understanding its utility in predicting subsequent development of Alzheimer-type dementia. Although individuals with SCD, by definition, perform in the objective "normal" range on standard clinical assessments [2], they may demonstrate subtle clinical changes. For example, a few studies have identified objective weaknesses in memory [13,14] and executive functioning [15,16] in those with SCD. Another study of community-dwelling older adults found that difficulties in everyday functioning were ⁵² The authors have declared that no conflict of interest exists.

^{*}Corresponding author. Tel.: +1 312-908-9339; Fax: +1 312-908-8789.

⁵⁴ E-mail address: stephaniekielb2012@u.northwestern.edu

⁵⁵ http://dx.doi.org/10.1016/j.jalz.2017.04.008 56 1552 5260/@ 2017 Published by Elsevier Ir

^{1552-5260/© 2017} Published by Elsevier Inc. on behalf of the Alzheimer's Association.

2

ARTICLE IN PRESS

commonly endorsed by participants who had a cognitive complaint [17]. However, these findings have not been consistently replicated, which could partially reflect the insensitivity of standard neuropsychological tests at detecting very subtle changes in individuals who are classified as "normal" for their demographic group.

The goal of the present study was to identify objective 125 functional and cognitive markers of SCD in a large cohort 126 of cognitively normal older adults from the National 127 Alzheimer's Coordinating Center (NACC) database [18]. 128 129 By harnessing the statistical power of a large data set, we 130 sought to identify very subtle but significant distinctions 131 that may have evaded detection in smaller samples. Prior 132 studies of postmortem cases from the NACC database 133 have reported associations between baseline SCD and subse-134 quent autopsy-confirmed AD pathology [9,10]. We expected 135 that our results would be consistent with these findings and 136 would therefore provide further support for the hypothesis 137 that SCD represents a preclinical stage of AD [2]. Specif-138 ically, we hypothesized that SCD would be associated with 139 weakness, albeit subtle, in everyday functional abilities 140 and in longitudinal cognitive performance on tests of 141 142 episodic memory and psychomotor speed, which are do-143 mains affected early in MCI and Alzheimer-type dementia 144 [19]. We also expected that baseline SCD would predict lon-145 gitudinal progression to clinical diagnoses of MCI and de-146 mentia. 147

149150**2. Methods**

148

151 *2.1. Sample* 152

153 Data for the present study were obtained from the NACC 154 database, which consists of longitudinal data collected at 34 155 previous or current National Institute on Aging-funded Alz-156 heimer's Disease Centers (ADCs) in the United States 157 (http://www.alz.washington.edu). The database contains 158 over 35,000 participants who span a broad range of cognitive 159 ability-from normal cognition to MCI and various forms of 160 dementia. Each ADC has its own system for recruiting and 161 enrolling participants. Thus, participants in the NACC data-162 base may come from self-referrals, recruitment activities in 163 the community, referrals from clinicians or family members, 164 or word-of-mouth advertising. 165

166 Data came from the second version of the Uniform Data 167 Set (UDS 2.0), which is a standardized battery of clinical and 168 cognitive evaluations administered on an annual basis to par-169 ticipants in all ADCs [20]. The research was approved by 170 institutional review boards at each ADC, and written 171 informed consent had been obtained from each participant 172 at enrollment; this included participant agreement to share 173 de-identified data collected at each center with NACC for 174 dissemination to researchers studying various aspects of 175 cognitive aging and dementia. 176

The present sample included participants in the database who were older than the age of 65 years and classified as "cognitively normal" at baseline based on the judgment of a trained clinician, a Mini–Mental State Examination score of 27 or above [21], and a Clinical Dementia Rating global score of 0 [22]. The sample was further restricted to participants who received longitudinal (i.e., at least two) annual evaluations and genotyping for the apolipoprotein E (APOE) ε 4 allele. Participants who endorsed more than Q3seven symptoms on the 15-item Geriatric Depression Scale (GDS-15) at baseline [23] were excluded from the sample, given that some cases of SCD may be an artifact of prominent depression [24,25]. The present analyses included 3915 participants from whom data had been collected between September 2005 and November 2013.

2.2. Determination of SCD

Several methods have been used to investigate the presence of SCD [26]. In the present sample, SCD was assessed within the context of the standardized evaluation protocol used at all ADCs. Specifically, the single yes-no question, "Does the subject report a decline in memory relative to previously attained abilities?" was systematically completed on the large number of individuals included for the current analysis. A trained clinician provides the response to this question after conducting a semistructured interview with the participant. Participants in the present study were classified based on whether SCD was determined to be present (SCD+ group) or absent (SCD- group) at their baseline visit. Although this single item may have failed to detect participants who may have been identified with more comprehensive measures, the proportion of participants with SCD in the sample (19.5%) was generally consistent with prevalence estimates that have been reported in other studies of community-dwelling older adults [1,17].

2.3. Descriptive variables

Demographic factors including age, gender, years of education, race, ethnicity, and primary language were examined in the present study. Family history of dementia and APOE ε 4 status were also accounted for, as the relationship between these AD risk factors and SCD is not well understood [27]. Participants who reported having at least one first-degree family member (i.e., a parent, sibling, or child) with dementia at any visit were classified as having a positive family history. Those with one or more APOE ε 4 alleles were defined as carriers and those without an ε 4 allele were defined as noncarriers.

2.4. Functional Activities Questionnaire

The Functional Activities Questionnaire (FAQ) served as the measure of everyday functional abilities [28]. This 10-item survey captures the level of ability in routine daily activities like paying bills and using the stove. A close informant completes the FAQ based on their observations of the participant over the past 4 weeks. Each item is rated on a 179

180

181

182

183

184

185

186

187

188

189

190

191

192

Download English Version:

https://daneshyari.com/en/article/8680063

Download Persian Version:

https://daneshyari.com/article/8680063

Daneshyari.com